Other > Off Topic

I was right.

<< < (4/4)

x4000:
Interesting.  Well, someone may start researching it.  There are currently 80 different vaccines in the works around the world for Covid-19 as of yesterday, in various stages of work and with information sharing between them.

My wife is staying on a bit longer on the Internal Review Board at her institution since there's a whole lot of Covid-19 research coming through the pipe all of a sudden and they need people to oversee it.  She was supposed to be out of that starting this month, but she has a long history with it and there's so much relevant research that is rapidly starting up that it's worth doing.

There's a lot of interesting things happening, and with the former head of the CDC pointing out the superbugs that everyone has been aware of for a long time in hospitals anyway... maybe that will also get some funding.  Hopefully before it gets too many people.

Draco18s:
It wouldn't help against COVID-19 itself, of course. Just the secondary infections.

* Draco18s pokes around a bit
Seems that there's been one clinical trial (in the US) so far.
https://jamanetwork.com/journals/jama/article-abstract/2725218

Was approved a year ago, but I don't see any outcome/results listed anywhere.

x4000:
From the trending part of the sidebar, later that year: https://jamanetwork.com/journals/jama/article-abstract/2737658

A pediatric patient with cystic fibrosis and a double-lung transplant received a genetically engineered 3-phage cocktail to treat a life-threatening antibiotic-resistant Mycobacterium abscessus infection for which all standard therapeutic options had been exhausted. Over 7 months of twice-daily intravenous infusions, as well as daily topical phage therapy, the 15-year-old patient’s surgical wound and skin lesions healed gradually and her lung and liver function improved. No adverse reactions to the treatment were reported.

Draco18s:

--- Quote from: x4000 on March 27, 2020, 11:44:13 am ---From the trending part of the sidebar, later that year: https://jamanetwork.com/journals/jama/article-abstract/2737658

A pediatric patient with cystic fibrosis and a double-lung transplant received a genetically engineered 3-phage cocktail to treat a life-threatening antibiotic-resistant Mycobacterium abscessus infection for which all standard therapeutic options had been exhausted. Over 7 months of twice-daily intravenous infusions, as well as daily topical phage therapy, the 15-year-old patient’s surgical wound and skin lesions healed gradually and her lung and liver function improved. No adverse reactions to the treatment were reported.

--- End quote ---

Nice. Must have missed seeing it.
Definitely a "single test subject" trial, which is a long way off from a wide-spectrum treatment.

x4000:
Yeah, I don't even know what kind of trial that is.  A human trial, but not general stage 3.

Navigation

[0] Message Index

[*] Previous page